|
시장보고서
상품코드
2091224
제1형 신경섬유종증 시장 규모, 점유율, 성장 분석 : 질환별, 치료법별, 유통 채널별, 최종사용자별, 환자층별, 지역별 - 업계 예측(2026-2033년)Neurofibromatosis Type 1 Market Size, Share, and Growth Analysis, By Disease Type (Plexiform Neurofibromas, Cutaneous Neurofibromas), By Treatment Type, By Distribution Channel, By End User, By Patient Population, By Region - Industry Forecast 2026-2033 |
||||||
세계의 제1형 신경섬유종증 시장 규모는 2024년에 82억 4,000만 달러로 평가되었으며, 2025년 90억 3,000만 달러에서 2033년까지 188억 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 9.6%로 성장할 것으로 전망됩니다.
세계 제1형 신경섬유종증(NF1) 시장은 이 질환에 대한 인식이 높아지고 유전자 진단 기술이 발전함에 따라 눈부신 성장을 이루고 있습니다. 이전에는 희귀질환으로 분류되었던 NF1이지만, 분자 염기서열 분석을 통해 더 많은 사례가 밝혀짐에 따라 환자 수가 증가하고 있습니다. FDA의 승인을 바탕으로 도입된 효과적인 치료법은 투자자들의 관심을 끌며, 새로운 치료법에 대한 자금 조달을 촉진하고 있습니다. 이러한 추세는 바이오의약품의 등장과 보험사의 유리한 환급 정책에 힘입어 더욱 가속화되고 있으며, 환자의 접근성을 높이고 매출을 끌어올리고 있습니다. 또한, AI를 활용한 진단 기술은 종양의 징후 탐지 능력을 대폭 향상시키고 임상시험 과정을 효율화함으로써, 보다 효율적인 의료 환경 조성을 촉진하고 있습니다. 이러한 혁신적인 치료법과 첨단 진단 도구의 시너지 효과는 NF1 시장의 성장과 투자자들의 신뢰를 더욱 높이고 있습니다.
세계 제1형 신경섬유종증 시장의 성장요인
전 세계적으로 임상시험 활동이 활발해짐에 따라 환자 등록 기회가 대폭 확대되고, 공동 연구 네트워크의 형성이 촉진되고 있습니다. 이에 따라 제1형 신경섬유종증에 대한 혁신적인 치료법의 평가가 가속화되고, 투자자들의 관심을 끌며, 제약 업계로부터 투자를 유치할 수 있는 유망한 치료법 파이프라인이 형성되고 있습니다. 그 결과, 이러한 환경은 필수적인 지원 서비스의 개발을 촉진하고 있으며, 시장 전체의 성장에 기여하는 동시에 전 세계적인 지속적 확대 전망을 높이고 있습니다. 또한, 이러한 추세는 새로운 치료 옵션에 대한 임상의들의 신뢰를 높이고 환자 지원 활동을 뒷받침함으로써 시장의 성장세를 더욱 가속화하고 있습니다.
세계 제1형 신경섬유종증 시장의 제약요인
세계 제1형 신경섬유종증 시장은 각 의료 제도 간에 일관성이 없는 보험 급여 정책으로 인해 제약을 받고 있습니다. 이로 인해 환자들이 새로운 치료법을 이용할 기회가 제한되고 있으며, 제약사 입장에서는 잠재적 수익에 대한 불확실성이 발생하고 있습니다. 이러한 재정적 장벽은 첨단 제품 파이프라인에 대한 투자를 저해하고, 혁신적인 치료법의 도입을 제한할 뿐만 아니라, 의료 서비스 제공자들이 비용 대비 효과가 더 높은 대체 요법을 우선적으로 선택하게 만드는 요인이 되고 있습니다. 그 결과, 이러한 상황은 시장의 성장을 저해하고 있으며, 이 치료 분야에서의 획기적인 연구에 대한 의욕을 떨어뜨리고 있습니다. 게다가 환자들은 본인 부담금을 지불해야 하는 경우가 많아, 이로 인해 지속적인 치료가 어려워지고 장기적인 건강 결과에 부정적인 영향을 미치므로, 이 시장이 직면한 과제를 더욱 심각하게 만들고 있습니다.
세계 제1형 신경섬유종증 시장의 동향
세계 제1형 신경섬유종증 시장에서는 의료 서비스 제공자들이 적극적인 질환 관리를 위해 NF1 돌연변이의 조기 발견을 우선시함에 따라, 통합적인 유전자 선별 검사로의 뚜렷한 추세가 나타나고 있습니다. 이러한 추세는 NF1에 대한 인식 제고, 차세대 염기서열 분석 기술의 발전, 그리고 맞춤형 치료 경로에 대한 중점화에 힘입어 가속화되고 있습니다. 조기 발견을 통해 적시에 치료에 나설 수 있게 되어, 합병증을 최소화하고 환자의 장기적인 예후를 개선함으로써, 보다 예측 가능한 의료 서비스를 실현할 수 있습니다. 그 결과, 각 제조사는 제품 개발 전략을 진단 통합에 맞춰 조정하고, 유전자 검사 기관과의 협력을 촉진하며, 정밀 의료에 중점을 둔 케어 솔루션에 대한 접근성을 확대함으로써, 궁극적으로 세계 시장에서의 입지를 강화하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 제1형 신경섬유종증 시장 규모 : 질환 유형별
세계의 제1형 신경섬유종증 시장 규모 : 치료 유형별
세계의 제1형 신경섬유종증 시장 규모 : 유통 채널별
세계의 제1형 신경섬유종증 시장 규모 : 최종사용자별
세계의 제1형 신경섬유종증 시장 규모 : 환자층별
세계의 제1형 신경섬유종증 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Neurofibromatosis Type 1 Market size was valued at USD 8.24 Billion in 2024 and is poised to grow from USD 9.03 Billion in 2025 to USD 18.8 Billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).
The global Neurofibromatosis Type 1 (NF1) market is witnessing significant growth due to an increasing recognition of the condition and advancements in genetic diagnostics. Previously classified as an orphan disease, NF1's patient population is expanding as molecular sequencing reveals more cases. The introduction of effective therapies, supported by successful FDA approvals, has attracted investor interest and funding for new treatments. This evolution is further accelerated by the emergence of biologics and favorable payer reimbursement policies, enhancing patient access and boosting sales. Additionally, AI-driven diagnostics significantly improve the detection of tumor manifestations and streamline clinical trial processes, fostering a more efficient healthcare landscape. This synergy of innovative therapies and enhanced diagnostic tools continues to amplify NF1 market growth and investor confidence.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurofibromatosis Type 1 market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Neurofibromatosis Type 1 Market Segments Analysis
Global neurofibromatosis type 1 market is segmented by disease type, treatment type, distribution channel, end user, patient population and region. Based on disease type, the market is segmented into Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Pathway Gliomas, Skeletal Manifestations and Other Manifestations. Based on treatment type, the market is segmented into Targeted Therapy, Surgical Resection, Chemotherapy, Radiation Therapy, Supportive Care and Gene Therapy (Emerging). Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Ambulatory Surgical Centers. Based on patient population, the market is segmented into Pediatric and Adult. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Neurofibromatosis Type 1 Market
The increased activity in clinical trials around the world has significantly improved the opportunities for patient enrollment and encouraged the formation of collaborative research networks. This has expedited the assessment of innovative therapies for neurofibromatosis type 1, leading to a promising pipeline of treatments that capture investor interest and draw in pharmaceutical investments. Consequently, this environment is fostering the development of essential supportive services, contributing to overall market growth and enhancing prospects for sustained expansion globally. Additionally, these trends bolster clinician confidence in new treatment options and support patient advocacy efforts, further energizing market momentum.
Restraints in the Global Neurofibromatosis Type 1 Market
The global market for Neurofibromatosis Type 1 is hindered by inconsistent reimbursement policies across various healthcare systems, which limit patient access to new treatments and create uncertainty for manufacturers about potential revenue. This financial barrier discourages investment in advanced product pipelines, restricting the adoption of innovative therapies and leading healthcare providers to favor more cost-effective alternatives. Consequently, this situation hampers market growth and diminishes motivation for groundbreaking research within this therapeutic area. Furthermore, patients often encounter out-of-pocket expenses that complicate continual treatment and adversely affect long-term health outcomes, compounding the challenges faced in this market.
Market Trends of the Global Neurofibromatosis Type 1 Market
The Global Neurofibromatosis Type 1 market is witnessing a notable trend towards integrated genetic screening, as healthcare providers prioritize early identification of NF1 mutations for proactive disease management. This trajectory is fueled by heightened awareness of NF1, advancements in next-generation sequencing technology, and an emphasis on personalized treatment pathways. Early detection facilitates timely therapeutic interventions, minimizes complications, and enhances long-term patient outcomes, resulting in a more predictable healthcare experience. Consequently, manufacturers are aligning their product development strategies with diagnostic integration, fostering collaborations with genetic laboratories and broadening access to precision-focused care solutions, ultimately strengthening their market positions globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Neurofibromatosis Type 1 Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Plexiform Neurofibromas
- Cutaneous Neurofibromas
- Optic Pathway Gliomas
- Skeletal Manifestations
- Other Manifestations
Global Neurofibromatosis Type 1 Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Targeted Therapy
- Selumetinib (Koselugo)
- Other MEK Inhibitors
- Surgical Resection
- Chemotherapy
- Radiation Therapy
- Supportive Care
- Gene Therapy (Emerging)
Global Neurofibromatosis Type 1 Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Neurofibromatosis Type 1 Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
Global Neurofibromatosis Type 1 Market Size by Patient Population & CAGR (2026-2033)
- Market Overview
- Pediatric
- Adult
Global Neurofibromatosis Type 1 Market Size & CAGR (2026-2033)
- North America (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
- US
- Canada
- Europe (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Treatment Type, Distribution Channel, End User, Patient Population)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AstraZeneca PLC (MedImmune/Alexion)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Springworks Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DeCiphera Pharmaceuticals LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Focus Pharma Holdings Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Leo Pharma A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
